The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination ...